Carregant...
Intravesical gemcitabine for non‐muscle invasive bladder cancer
BACKGROUND: It remains unclear whether people with non‐muscle invasive bladder cancer (NMIBC) benefit from intravesical gemcitabine compared to other agents in the primary or recurrent setting following transurethral resection of a bladder tumor. This is an update of a Cochrane Review first publishe...
Guardat en:
| Publicat a: | Cochrane Database Syst Rev |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Ltd
2021
|
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8202966/ https://ncbi.nlm.nih.gov/pubmed/34125951 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD009294.pub3 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|